Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers.

Cui, Yingzi; Cui, Dongyang; Ren, Xinran; Chen, Xuesong; Liu, Guangwen; Liu, Zhengzhi; Wang, Yanli; Qu, Xinyao; Zhao, Yicheng; Yang, Haimiao

Cui, Yingzi; Cui, Dongyang; Ren, Xinran; Chen, Xuesong; Liu, Guangwen; Liu, Zhengzhi; Wang, Yanli; Qu, Xinyao; Zhao, Yicheng; Yang, Haimiao.

Afiliação

Cui Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Cui D; Jiangsu Hengrui Medicine Co.,Ltd., Jiangsu, China.
Ren X; Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China.
Chen X; School of Pharmacy, Jilin University, Jilin, China.
Liu G; Clinical Medical College, Changchun University of Chinese Medicine, Jilin, China.
Liu Z; Jilin Province Honesty Medical Technology Consulting Co., Ltd., Jilin, China.
Wang Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Qu X; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Zhao Y; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Yang H; Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.

Front Pharmacol ; 12: 660541, 2021.

Article em En | MEDLINE | ID: mdl-34149414

Palavras-chave

SHR-1309 injection; bioequivalence; immunogenicity; perjeta®; pharmacokinetics; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google